Antimicrobial therapy

Phase 3
Idiopathic Pulmonary Fibrosis
Intervention Type:
Oral Drug
Funder Type:
Organization | University

Drug Details

Antimicrobial therapy: Co-trimoxazole or Doxycycline

Study Purpose

The purpose of this study is to compare the effect of standard care, versus standard of care plus antimicrobial therapy (co-trimoxazole or doxycycline), on clinical outcomes in patients diagnosed with idiopathic pulmonary fibrosis (IPF). Our overall hypothesis is that reducing harmful microbial impact with antimicrobial therapy will reduce the risk of non-elective, respiratory hospitalization or death in patients with Idiopathic Pulmonary Fibrosis (IPF). 

This drug has no clinical trials actively recruiting patients at this time.